menu
    • menu
    [{"orgOrder":0,"company":"Technical University of Munich","sponsor":"Carl Zeiss Meditec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fluorescein Sodium","moa":"Retina \/ blood vessels","graph1":"Oncology","graph2":"Phase II","graph3":"Technical University of Munich","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Technical University of Munich \/ Carl Zeiss Meditec","highestDevelopmentStatusID":"8","companyTruncated":"Technical University of Munich \/ Carl Zeiss Meditec"},{"orgOrder":0,"company":"UpTru Inc.","sponsor":"Medicor Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fluorescein Sodium","moa":"Retina \/ blood vessels","graph1":"Undisclosed","graph2":"Phase I","graph3":"UpTru Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UpTru Inc. \/ Medicor Research","highestDevelopmentStatusID":"6","companyTruncated":"UpTru Inc. \/ Medicor Research"},{"orgOrder":0,"company":"AdventHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Fluorescein Sodium","moa":"Retina \/ blood vessels","graph1":"Neurology","graph2":"Phase IV","graph3":"AdventHealth","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdventHealth \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AdventHealth \/ Undisclosed"},{"orgOrder":0,"company":"MediBeacon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fluorescein Sodium","moa":"Retina \/ blood vessels","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"MediBeacon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MediBeacon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MediBeacon \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Fluorescein Sodium

    Menu

    Fluorescein Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Technical University of Munich

                            Country arrow
                            CPhI India
                            Not Confirmed

                            Technical University of Munich

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorescein Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Carl Zeiss Meditec

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperati...

                            Details : Alcon (Fluorescein Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Alcon

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 22, 2020

                            Lead Product(s) : Fluorescein Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Carl Zeiss Meditec

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UpTru Inc.

                            Country arrow
                            CPhI India
                            Not Confirmed

                            UpTru Inc.

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorescein Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Medicor Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Study of Oral Fluorescite to Confirm the Authenticity of Point of Care Urine Samples

                            Details : Fluorescein Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2019

                            Lead Product(s) : Fluorescein Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Medicor Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MediBeacon

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            MediBeacon

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorescein Sodium

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

                            Details : Fluorescein Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Retinal Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 05, 2019

                            Lead Product(s) : Fluorescein Sodium

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AdventHealth

                            Country arrow
                            CPhI India
                            Not Confirmed

                            AdventHealth

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorescein Sodium

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions

                            Details : Fluorescein Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cerebrovascular Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 23, 2015

                            Lead Product(s) : Fluorescein Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth